Industry Featured Article
In a recent interview with Life Sciences Review, Allucent Senior Director, Global Head of Programming, Stephen Apps, explores how to foster excellence in clinical programming solutions. The meaningful data harnessed through clinical programming has immense potential to yield successful outcomes for clinical trials. However, ever-changing regulations can make this part of the clinical trial process difficult to navigate.y
At Allucent, our distinction in Biometrics is grounded in a deep knowledge of complex indications and therapeutic areas. With extensive experience designing and implementing drug development plans from preclinical through Phase IV clinical trials, our data science experts consistently and accurately anticipate risks, prevent delays, avoid unnecessary expenses, efficiently distribute resources, and develop realistic yet zealous timelines.
During this interview, Stephen digs into pertinent topics such as leveraging AI, how the field of clinical programming has evolved, and common roadblocks in the current market. Click on the button below to read more.
